Based on the AstraZeneca PLC ADR stock forecast from 6 analysts, the average analyst target price for AstraZeneca PLC ADR is USD 87.75 over the next 12 months. AstraZeneca PLC ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AstraZeneca PLC ADR is Bullish , which is based on 13 positive signals and 4 negative signals. At the last closing, AstraZeneca PLC ADR’s stock price was USD 65.35. AstraZeneca PLC ADR’s stock price has changed by -1.85% over the past week, +1.70% over the past month and -1.43% over the last year.
No recent analyst target price found for AstraZeneca PLC ADR
No recent average analyst rating found for AstraZeneca PLC ADR
Company Overview AstraZeneca PLC ADR
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Address: 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA Read Less
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga...Read More
Frequently Asked Questions About AstraZeneca PLC ADR (AZN) Stock
Based on ratings from 6 analysts AstraZeneca PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 7 buy, sell and 1 hold ratings.
AZN stock's dividend yield is 2.20%.
Our analysis grades AZN stock's dividend yield at F. This means that AZN stock's dividend yield is above 25% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AZN may be a poor dividend stock for its sector.
Based on targets from 6 analysts, the average taret price for AZN is USD 87.75 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 78.
AZN stock's Price/Earning ratio is 32.51.
Our analysis grades AZN stock's Price / Earning ratio at C-. This means that AZN stock's Price/Earning ratio is above 29% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AZN may be undervalued for its sector.
The last closing price of AZN's stock was USD 65.35.
The most recent market capitalization for AZN is USD 209.66B.
Based on targets from 6 analysts, the average taret price for AZN is projected at USD 87.75 over the next 12 months.
This means that AZN's stock price may go up by +34.28% over the next 12 months.
We can't find any ETFs which contains AstraZeneca PLC ADR's stock.
As per our most recent records AstraZeneca PLC ADR has 89,900 Employees.
AstraZeneca PLC ADR's registered address is 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA.
You can get more information about it from AstraZeneca PLC ADR's website at https://www.astrazeneca.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About AstraZeneca PLC ADR (AZN) Stock
Based on ratings from 6 analysts AstraZeneca PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 7 buy, sell and 1 hold ratings.
AZN stock's dividend yield is 2.20%.
Our analysis grades AZN stock's dividend yield at F. This means that AZN stock's dividend yield is above 25% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AZN may be a poor dividend stock for its sector.
Based on targets from 6 analysts, the average taret price for AZN is USD 87.75 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 78.
AZN stock's Price/Earning ratio is 32.51.
Our analysis grades AZN stock's Price / Earning ratio at C-. This means that AZN stock's Price/Earning ratio is above 29% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AZN may be undervalued for its sector.
The last closing price of AZN's stock was USD 65.35.
The most recent market capitalization for AZN is USD 209.66B.
Based on targets from 6 analysts, the average taret price for AZN is projected at USD 87.75 over the next 12 months.
This means that AZN's stock price may go up by +34.28% over the next 12 months.
We can't find any ETFs which contains AstraZeneca PLC ADR's stock.
As per our most recent records AstraZeneca PLC ADR has 89,900 Employees.
AstraZeneca PLC ADR's registered address is 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA.
You can get more information about it from AstraZeneca PLC ADR's website at https://www.astrazeneca.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AZN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
